Design, Synthesis, and Biological Evaluation of Notopterol Derivatives as Triple Inhibitors of AChE/BACE1/GSK3β for the Treatment of Alzheimer's Disease.

Tideglusib showed a trend to reduce GSK3β activity in the phase IIa clinical trial, but it did not show a significant clinical effect due to the absence of its primary endpoint and some secondary endpoints in the phase IIb clinical trial ( Figure 3 ). 15 Early studies proposed that the hypotheses of Aβ, tau, and cholinergic pathology were carried out on different timelines.

also in 53,322 other papers